Sector revisions Harmony Biosciences Holdings, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
28.33 ^USD	-0.63%		-0.74%	-24.29%

Feb. 25	Deutsche Bank Adjusts Harmony Biosciences PT to $30 From $31, Maintains Hold Rating	MT
Feb. 24	Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for 2026	CI

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	HARMONY BIOSCIENCES HOLDINGS, INC.							11
	ELI LILLY AND COMPANY							29
	JOHNSON & JOHNSON							24
	ABBVIE INC.							29
	ROCHE HOLDING AG							19
	NOVARTIS AG							21
	ASTRAZENECA PLC							21
	MERCK & CO., INC.							27
	AMGEN INC.							28
	GILEAD SCIENCES, INC.							27
	NOVO NORDISK A/S							21
	PFIZER INC.							26
	BRISTOL-MYERS SQUIBB COMPANY							25
	VERTEX PHARMACEUTICALS INCORPORATED							27
	GSK PLC							20
	SANOFI							23
	CHUGAI PHARMACEUTICAL CO., LTD.							15
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							15
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							17
	HALEON PLC							16
	Average							22
	Weighted average by Cap.							25